Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Radiation Therapy
  •  Immunology
  •  Haemato-Oncology
  •  Gastrointestinal Cancer
  •  Blood Cancer
  •  Cervical Cancer
  •  Paediatric Cancers
  •  Lymphoma

Abstract

Citation: Clin Oncol. 2023;8(1):2005.DOI: 10.25107/2474-1663.2005

A Comprehensive Study of ROS1 Fusion in Patients with Non-Small-Cell Lung Cancer Using Novel ROS1 Immunohistochemistry Clone (SP384)

Wang Y, Wang Y, Jin Y, Cai X, Shen X, Zhou X and Li Y

Department of Pathology, Fudan University Shanghai Cancer Center, China
Department of Oncology, Shanghai Medical College, Fudan University, China

*Correspondance to: Yuan LI 

 PDF  Full Text Research Article | Open Access

Abstract:

Background: The ROS1 rearrangement is an important oncogenic target in lung cancer patients. Immunohistochemistry (IHC) is a commonly used method to identify potential ROS1 rearrangement in routine clinical practice. In this study, we evaluated a novel ROS1 immunohistochemistry clone (SP384) and investigated the correlation between different ROS1 fusion variants and IHC staining features. Methods: A total of 1380 lung cancers were screened by Next-Generation Sequencing (NGS) or Fluorescence in situ Hybridization (FISH) analysis for ROS1 rearrangement prediction 37 ROS1 NGS/FISH-positive and 173 ROS1 NGS/FISH-negative NSCLC cases were selected for review in this study. All specimens were screened with a novel anti-ROS1 IHC clone (SP384) from Ventana medical systems and a previous anti-ROS1 IHC clone (D4D6) from Cell Signaling Technology. The IHC expression results were evaluated by two pathologists using H-score criteria. Next Generation Sequencing (NGS) is based on a targeted panel of 68 genes. Results: A H-score of 150 or higher could be an optimal cut-off value for this novel anti-ROS1 IHC clone (SP384) to discriminate ROS1 rearranged cases with ROS1 non-rearranged cases with 90% sensitivity and 99% specificity. Compared with anti-ROS1 clone D4D6, SP384 has a higher sensitivity without compromising specificity. Different fusion partners have distinctive IHC staining features and several novel fusion alterations were found. CD74 is the most frequent occurring fusion partner with a strong and diffuse staining pattern. Two ROS1 mutant cases in negative control group were also found presenting moderate, membranous staining with an H-score above 150. Conclusion: The novel anti-ROS1 IHC clone (SP384) could be an outstanding diagnostic alternative in routine clinical practice. Furthermore, this study highlights the importance of IHC in clinical practice that it can be a very supportive tool when used with molecular approaches to interpret fusion alterations like ROS1 and help accurately predict the efficacy of targeted therapy.

Keywords:

ROS1; Immunohistochemistry; Next-generation sequencing; Fusion partners; Functional outcomes; Targeted therapy

Cite the Article:

Wang Y, Wang Y, Jin Y, Cai X, Shen X, Zhou X, et al. A Comprehensive Study of ROS1 Fusion in Patients with Non-Small-Cell Lung Cancer Using Novel ROS1 Immunohistochemistry Clone (SP384). Clin Oncol. 2023;8:2005..

Search Our Journal

Journal Indexed In

Articles in PubMed

NMR Metabolomics in Ionizing Radiation
 PubMed  PMC  PDF  Full Text
Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Thromboxane-Prostanoid Receptor Signaling as Potential Therapy for Pulmonary Fibrosis
 PDF  Full Text
Absolute dPCR Quantification of MicroRNAs by Absolute dPCR for the Diagnostic Screening of Colon Cancer
 PDF  Full Text
View More...